Suzhou Municipal Hospital
Clinical Trials
9
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)β’ Click on a phase to view related trials
A Technique Improves Urinary Continence in Patients Undergoing Laparoscopic Radical Prostatectomy
- Conditions
- Posterior Bladder Wall ReconstructionAnterior Bladder Wall ReconstructionAnterior Bladder Wall Suspension
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Suzhou Municipal Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT06754488
- Locations
- π¨π³
Suzhou Municipal Hospital, Suzhou, Jiangsu, China
Safety and Efficacy Study of NGGT006 in Refractory Hypercholesterolemia Patients
- Conditions
- Familial HypercholesterolemiaRefractory Hypercholesterolemia
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Suzhou Municipal Hospital
- Target Recruit Count
- 9
- Registration Number
- NCT06293729
Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE HTN-III)
- Conditions
- HypertensionBlood PressureCardiovascular Diseases
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Suzhou Municipal Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06283758
- Locations
- π¨π³
The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
π¨π³The first Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
π¨π³Affiliated Hospital of Nantong University, Nantong, Jiangsu, China
The Effect of LIPUS on the Maturation of Newly Constructed Autogenous AVF
- Conditions
- Uremia; Chronic
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Suzhou Municipal Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06249373
- Locations
- π¨π³
The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Suzhou, Jiangsu, China
Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)
- Conditions
- Cervical Cancer
- Interventions
- Drug: Chemoradiotherapy (small pelvic) + ZimberelimabDrug: Chemoradiotherapy + Adjuvant chemotherapy and Zimberelimab
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Suzhou Municipal Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT05872724
- Locations
- π¨π³
The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu, China
- Prev
- 1
- 2
- Next
News
Innovent Initiates Phase 3 Trial of Picankibart for Psoriasis Patients with Inadequate IL-17 Response
Innovent Biologics has dosed the first participant in a Phase 3 study evaluating picankibart, an anti-IL-23p19 antibody, for psoriasis patients who had inadequate response to prior IL-17 inhibitor treatment.